WO2021136408A1 - 一种基于leaper技术治疗mps ih的方法和组合物 - Google Patents
一种基于leaper技术治疗mps ih的方法和组合物 Download PDFInfo
- Publication number
- WO2021136408A1 WO2021136408A1 PCT/CN2020/141506 CN2020141506W WO2021136408A1 WO 2021136408 A1 WO2021136408 A1 WO 2021136408A1 CN 2020141506 W CN2020141506 W CN 2020141506W WO 2021136408 A1 WO2021136408 A1 WO 2021136408A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arrna
- seq
- target
- rna
- idua
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 73
- 238000005516 engineering process Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims description 9
- 230000035772 mutation Effects 0.000 claims abstract description 64
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 28
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 14
- 229960005305 adenosine Drugs 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 139
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 106
- 125000003729 nucleotide group Chemical group 0.000 claims description 62
- 239000002773 nucleotide Substances 0.000 claims description 61
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 238000007385 chemical modification Methods 0.000 claims description 21
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 239000013603 viral vector Substances 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 102220004234 rs121965019 Human genes 0.000 claims description 15
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 14
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 239000002502 liposome Substances 0.000 claims description 13
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims description 12
- 102100035028 Alpha-L-iduronidase Human genes 0.000 claims description 11
- 108091026890 Coding region Proteins 0.000 claims description 11
- 101150022680 IDUA gene Proteins 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 7
- 238000001638 lipofection Methods 0.000 claims description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 238000002716 delivery method Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 5
- 108020004394 Complementary RNA Proteins 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 52
- 102000004190 Enzymes Human genes 0.000 description 47
- 108090000790 Enzymes Proteins 0.000 description 47
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- 210000005229 liver cell Anatomy 0.000 description 25
- 238000001890 transfection Methods 0.000 description 19
- 210000002950 fibroblast Anatomy 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 238000010357 RNA editing Methods 0.000 description 17
- 230000026279 RNA modification Effects 0.000 description 17
- 230000008685 targeting Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- QSLFDILMORXPKP-UHFFFAOYSA-N (3-methylimidazol-3-ium-1-yl)-methylsulfanylphosphinate Chemical compound CSP([O-])(=O)N1C=C[N+](C)=C1 QSLFDILMORXPKP-UHFFFAOYSA-N 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 11
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000015178 Hurler syndrome Diseases 0.000 description 8
- 108091027974 Mature messenger RNA Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 6
- 108010003381 Iduronidase Proteins 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000024825 childhood disintegrative disease Diseases 0.000 description 6
- 102000056929 human IDUA Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 4
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 201000002883 Scheie syndrome Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000010442 DNA editing Methods 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100011486 Mus musculus Elf4 gene Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 102000046949 human MSC Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013402 definitive screening design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003052 fractional factorial design Methods 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000002048 multi walled nanotube Substances 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 101150105899 ppiB gene Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009392 systemic autoimmunity Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
Definitions
- This application belongs to the field of gene editing therapy. Specifically, it relates to a method for targeted editing of RNA to treat MPS IH based on LEAPER (Leveraging Endogenous ADAR for Programmable Editing on RNA) technology, which includes the use of LEAPER technology to perform RNA transfer from A to I. Site-directed editing of the base in vivo to treat diseases caused by G>A mutations, such as MPS IH.
- LEAPER Leveraging Endogenous ADAR for Programmable Editing on RNA
- Hurler syndrome also known as Mucopolysaccharidoses IH (MPS IH), or Mucopolysaccharidoses IH
- MPS IH Mucopolysaccharidoses IH
- IH/S ⁇ -L-iduronidase
- AR Chromosomal recessive genetic disease
- the root cause of Heller’s syndrome is the mutation of the IDUA gene located on human chromosome 4 in 4p16.3, which encodes the IDUA protein. So far, there are more than 200 pathogenic mutations, of which one is the most common type.
- ⁇ -L-iduronidase is responsible for the degradation of Glycosaminoglycans (GAGs) in cell lysosomes.
- GAGs Glycosaminoglycans
- Patients with Hurler syndrome vary greatly among individuals. They can be normal at birth. The earliest sign at 3-6 months is rough facial contours, followed by symptoms such as frontal bone protrusion, skeletal deformities, growth arrest, and language disorders. Usually live less than 10 years old.
- ERT enzyme replacement therapy
- HSCT hematopoietic stem cell transplantation
- HSCT hematopoietic stem cell transplantation as therapy for Hurler Syndrome.Tolar,J(2008).Bone marrow transplantation.41.531-5.10.1038/sj.bmt.1705934).
- the principle of the gene editing technology under study for the treatment of Heller’s syndrome is to use zinc finger nuclease (ZFN) and adeno-associated virus (AAV) to encode the cDNA sequence of the normal IDUA protein.
- ZFN zinc finger nuclease
- AAV adeno-associated virus
- CRISPR genome editing technology
- Cas9 CRISPR
- CRISPR-based DNA editing technology must express Cas9 or other nucleases with similar functions through exogenous expression, causing the following problems.
- nucleases that usually require exogenous expression usually have a relatively large molecular weight, which makes the efficiency of their delivery into the body through a viral vector drastically reduced.
- nuclease due to the exogenous expression of nuclease, there is a potential for off-target nuclease, which will make its application have a potential carcinogenic risk.
- the exogenously expressed nuclease is found in bacteria, rather than naturally occurring in humans or mammals, which makes it possible to cause an immune response in the patient's body, which may cause damage to the patient himself on the one hand, on the other hand It may also neutralize the exogenously expressed nuclease, thereby losing its proper activity, or hindering further intervention and treatment.
- RNA editing technology called REPAIR (RNA Editing for Programmable A to I Replacement) (RNA editing with CRISPR-Cas13, Cox et al., 2017), which uses exogenous expression Cas13-ADAR fusion protein and single guide RNA (sgRNA) can also achieve A to I editing of target RNA, but this method, like CRISPR technology, still requires the expression of foreign protein. Unable to solve the problems caused by the expression of foreign proteins.
- RESTORE nucleic acid editing technology Recruiting endogenous ADAR to specific trans for oligonucleotide-mediated RNA editing, Merkle et al., 2019.
- This technology can get rid of the dependence on foreign proteins.
- RESTORE technology needs to have high editing efficiency under the premise of IFN- ⁇ , and IFN- ⁇ is a key factor that determines the development and severity of autoimmunity (Interferon- ⁇ and systemic autoimmunity, Pollard et al., 2013, This makes the application of the technology in the medical field greatly reduced.
- a guide RNA is also used in the RESTORE technology, and the guide RNA used is a chemically synthesized oligonucleotide, and the synthesized oligonucleotide A large number of chemical modifications need to be artificially introduced to ensure its stability.
- the dRNA contains a complementary RNA sequence that hybridizes with the target RNA, and the dRNA can recruit adenosine deaminase (ADAR) that acts on the RNA to deaminate the target adenosine (A) in the target RNA.
- ADAR adenosine deaminase
- This application provides a brand new G to A mutation in the IDUA pathogenic gene of Hurler syndrome, especially the mutation with the highest proportion (NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter))
- the technical solution enables it to accurately edit the mutation site on the target RNA.
- this application provides at least the following technical solutions:
- a method for targeted editing of target RNA in target cells based on LEAPER technology wherein the target RNA is an RNA containing a G to A mutation in the IDUA gene transcript, and the method includes:
- RNA adenosine deaminase recruiting RNA
- arRNA adenosine deaminase recruiting RNA
- the arRNA includes a complementary RNA sequence that hybridizes with the target RNA
- ADAR adenosine deaminase
- the arRNA introduces base C paired with target A. In some embodiments, the arRNA introduces base A that is paired with target A. In some embodiments, the arRNA introduces base U paired with target A. 3. The method according to any one of items 1-2, wherein the arRNA is about 151-61 nt, 131-66 nt, 121-66 nt, 111-66 nt, 91-66 nt or 81-66 nt in length. This application discloses and covers any natural number within the stated number range.
- RNA is an RNA containing a mutation site of NM_000203.4 (IDUA)-c.1205G-A (p.Trp402Ter).
- arRNA comprises the following sequence: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17. SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 34.
- arRNA comprises a sequence selected from the group consisting of SEQ ID NO: 44 or SEQ ID NO: 52.
- the first 3 and last 3 nucleotides of the sequence were modified by 2 ⁇ -OMe,
- the first 3 and last 3 internucleotide linkages are all phosphorothioate linkages
- the 3'nearest neighbor of the target base is 2'-OMe modified A
- the 5'nearest neighbor of the targeted base is 2'-OMe modified C
- the target base and its 3’ nearest neighbor base and 5’ nearest neighbor base are respectively connected by phosphorothioate bonds
- the first 5 and last 5 nucleotides are modified by 2 ⁇ -OMe, and
- the first 5 and last 5 nucleotide linkages are phosphorothioate linkages.
- the chemical modification is selected from one or more of the following:
- CM1 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time, all U in the sequence are 2 ⁇ -OMe. ⁇ -OMe modification;
- CM2 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 3'of the base is targeted The nearest neighbor base is 2 ⁇ -OMe modified A;
- CM3 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 5'of the base is targeted The nearest neighbor base is 2 ⁇ -OMe modified C;
- CM4 The first 3 and last 3 nucleotides of the sequence are modified by 2'-OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the target base and its 3' The nearest neighbor base and the 5'nearest neighbor base are respectively connected by phosphorothioate bonds; and
- CM6 The first 5 and last 5 nucleotides of the sequence are modified by 2'-OMe respectively, and the connections between the first 5 and last 5 nucleotides are phosphorothioate linkages. 13. The method according to any one of items 1-9, wherein the construct encoding the arRNA is a linear nucleic acid strand, a viral vector or a plasmid.
- the viral vector is an adeno-associated virus (AAV) vector or a lentiviral expression vector.
- AAV adeno-associated virus
- the target cells include hepatocytes or fibroblasts.
- An arRNA or its coding sequence for targeted editing of target RNA in target cells by LEAPER technology comprising any of the following sequences or consisting of any of the following sequences: SEQ ID NO: 14, SEQ ID NO: 15. SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 44 or SEQ ID NO: 52.
- composition, preparation, kit or biological product comprising the arRNA described in Item 18 or its coding sequence, or the plasmid, viral vector, liposome or lipid nanoparticle described in Item 19.
- a method for treating MPS IH in an individual comprising using the method described in any one of items 1-17 to correct the G to A mutations in target cells of the individual that are associated with MPS IH disease.
- the application also relates to the use of a sequence selected from the following in the preparation of drugs for the treatment of MPS IH disease: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 9, SEQ ID NO: 13 , SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 44, or SEQ ID NO: 52.
- RNA in target cells such as hepatocytes or fibroblasts
- accurately repair disease-causing mutation sites such as NM_000203.4 (IDUA)-c.1205G-A(p.Trp402Ter) mutation restores the normal expression of the protein encoded by RNA in the body, achieving the purpose of treating MSP and IH.
- Figure 1 shows the detection of IDUA genotype on GM06214 cells.
- FIG. 1 shows the test of cell electrotransfection conditions.
- Figure 3A-B shows the design of arRNA for IDUA pre-mRNA and mRNA to test the cell function after editing; and the design of arRNA for IDUA pre-mRNA and mRNA to test the cell editing efficiency.
- Figure 4A shows the design of the IDUA-reporter cell line; and Figure 4B shows the editing efficiency of detecting different lengths of arRNA (symmetrically truncated) on the 293T-IDUA-Reporter.
- Figures 5A-B show the detection of enzyme activity and editing efficiency at different time points after transfection of different lengths (symmetrically truncated) arRNA on GM06214 cells.
- Figure 6 shows the detection of IDUA enzyme activity and editing efficiency after arRNA (symmetric truncation, 3 ⁇ truncation and 5 ⁇ truncation) was transfected with lipofectmine RNAiMAX in GM06214 cells.
- Figure 7A shows that the arRNA targeting the human IDUA mutation site is preferably between 55-c-25 and 55-c-10, and the bases are reduced one by one at the 3'end, and the best is selected by enzyme activity detection using GM06214 cells.
- length. 7B shows that the arRNA targeted to the IDUA mutation site of the mouse is between 55-c-55 and 55-c-10, gradually decreasing every 5 bases at the 3'end, using MPSI mouse MEF cells (MSPI MEF (MSPI mouse embryo fibroblast)) Select the best arRNA length sequence through enzyme activity detection.
- MSPI MEF MSPI mouse embryo fibroblast
- Figure 8A shows that under the preferred two 3 ⁇ end lengths, the 5 ⁇ end length is gradually shortened to screen out the optimal length range.
- Figure 8B shows that after the 3 ⁇ end length is fixed to 14 nt, the 5 ⁇ end is truncated base by base.
- the arRNA formed after a short period of time affects the enzyme activity, and the optimal arRNA length is screened by combining Figures 8A and 8B.
- Figure 9 shows a comparison of the effects of different chemical modifications on arRNA editing efficiency (represented by enzyme activity) under the preferred two arRNA lengths.
- Figures 10A-D show the editing efficiency and the ability of human and mouse arRNA to edit IDUA mRNA and the ability to produce a functional IDUA protein after editing under different arRNA concentrations under a combination of preferred lengths and preferred chemical modification methods.
- Figures 11A-D show the IDUA enzyme activity measured in human or murine cells at different times after a single transfection under the combination of the preferred length and the preferred chemical modification method.
- Figures 12A-B show the editing efficiency of targeted sites achieved by delivering arRNA in different ways in primary liver cells of humans and mice.
- Figure 13 shows the editing efficiency of arRNA targeting IDUA delivered by LNP on primary cultured human and mouse liver cells.
- Figure 14 shows the editing efficiency of IDUA in mouse liver cells after the screened arRNA (SEQ ID NO: 52) targeting mouse IDUA mutations is packaged into LNP and administered to mice via the tail vein at different concentrations for 24hrs .
- RNA editing refers to a natural process that exists in eukaryotic cells. RNA editing is the editing from base A (adenine) to I (hypoxanthine) that occurs at the RNA level after DNA transcription and before protein translation. , Hypoxanthine is recognized as G during translation, and the editing of A to I in RNA diversifies the transcriptome. Through site-specific and precise changes to RNA molecules, the total amount of RNA is increased several times. This editing is catalyzed by ADAR (Adenosine Deaminase Acting on RNA) protease, and is called site-directed RNA editing. Editing can occur in coding regions including intron and exon sequences, and can also occur in non-coding regions. Editing in coding regions can redefine protein coding sequences.
- ADAR AdAR
- LEAPER technology refers to a technology for RNA editing by using engineered RNA to recruit endogenous ADAR, and refers to the RNA editing technology as reported in WO2020074001A1.
- adenosine deaminase refers to a type of adenosine deaminase that is widely expressed in various tissues of eukaryotes (including humans and other mammals), which can catalyze adenosine in RNA molecules. Conversion of A to Inosine I. In the process of protein synthesis in eukaryotes, I is usually interpreted as G for translation.
- the "complementarity" of a nucleic acid refers to the ability of one nucleic acid to form hydrogen bonds with another nucleic acid through traditional Watson-Crick base pairing. Percent complementarity represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (i.e., Watson-Crick base pairing) with another nucleic acid molecule (e.g., about 5, 6, 7, 8, 9, 10 out of 10). These are respectively about 50%, 60%, 70%, 80%, 90% and 100% complementary). "Fully complementary” means that all consecutive residues of the nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in the second nucleic acid sequence.
- substantially complementary means that within a region of about 40, 50, 60, 70, 80, 100, 150, 200, 250 or more nucleotides, at least about 70%, 75%, 80
- base or a single nucleotide according to the Watson-Crick base pairing principle, when A is paired with T or U, and C is paired with G or I, it is called complement or match, and vice versa; and other bases Base pairing is called non-complementarity or mismatch.
- Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized by hydrogen bonds between the bases of nucleotide residues.
- the hydrogen bonding can occur through Watson Crick base pairing, Hoogstein binding, or in any other sequence-specific manner.
- a sequence that can hybridize to a given sequence is called the "complementary sequence" of the given sequence.
- electrotransfection refers to electroporation transfection technology, which temporarily forms small holes or openings in the cell membrane after an electric field is applied to cells for a few microseconds to a few milliseconds to deliver large molecules such as DNA to the cells.
- liposome transfection refers to a transfection technique that uses liposomes as delivery vehicles in vivo and in vitro. Liposomes include neutral liposomes and cationic liposomes.
- the neutral liposomes use lipid membranes to encapsulate macromolecules, such as nucleic acids, and deliver the macromolecules into the cell membrane by means of lipid membranes; cationic lipids
- the body is positively charged, and the transferred macromolecules are not pre-embedded in it, but because the macromolecules themselves are negatively charged, they automatically bind to the positively charged liposomes, forming a macromolecule-cation liposome complex
- the substance, which adsorbs to the negatively charged cell membrane surface, is delivered into the cell through endocytosis.
- lipid-nanoparticle (LNP) delivery refers to the transmembrane delivery of macromolecules, such as nucleic acids, proteins, etc., into cells through lipid nanoparticles.
- lipid nanoparticles refer to particles synthesized by mixing two phases, including an ethanol phase containing ionizable lipids, auxiliary phospholipids, cholesterol, and PEG lipids, and an acidic aqueous phase containing macromolecules such as nucleic acids and proteins.
- LNP encapsulated with RNA can enter the cytoplasm through endocytosis.
- the NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter) mutation refers to the mutation from G to A at position 1205 in the transcript of IDUA gene number 000203.4, which causes the transcript
- the coding sequence of tryptophan (Trp) at position 402 of the translated peptide chain is converted into a stop codon (Ter), so that all amino acids after position 402 are deleted in the final translated amino acid, thereby losing the enzymatic activity of IDUA.
- Patients with this mutation will affect the degradation of glucosaminoglycan in the cell lysosome due to the lack of active ⁇ -L-iduronidase, and eventually cause teratogenic or even death to the patient.
- the scheme in this application can restore the activity of IDUA enzyme by reversing this mutation at the transcription level.
- target RNA refers to a target RNA to be edited, which contains adenosine (A) to be edited.
- the target RNA may be mature mRNA or mRNA precursor. In this application, mRNA precursors are more preferred.
- the cell containing the "target RNA” is referred to as the target cell.
- the adenosine to be edited is called “target base”, “target adenosine” or “target A”. In this application, “target base”, “target adenosine” or “target A” can be used interchangeably.
- the base adjacent to the target adenosine at the 5'end of the target RNA is called the "5' adjacent base”; the base adjacent to the target adenosine at the 3'end of the target RNA is called the “3' adjacent base” Base”; the base triplet composed of the target base and its 3'and 5'adjacent bases is referred to herein as the "target base triplet”.
- target base the base opposite to the target base on arRNA
- the base adjacent to the target base at the 5'end of arRNA is called "5".
- the base triplet of is referred to herein as the "targeted base triplet".
- the term "construct” refers to a nucleic acid vector containing a certain nucleic acid sequence
- the nucleic acid vector can be a linear nucleic acid molecule, a plasmid, a viral vector, or the like.
- the nucleic acid molecule may be single-stranded or double-stranded.
- the nucleic acid sequence may be a DNA sequence or an RNA sequence. In some embodiments, the nucleic acid sequence directly performs its function without being transcribed, translated, or expressed. In some embodiments, the nucleic acid sequence is a DNA sequence, which functions as an RNA molecule after being transcribed to form RNA.
- the nucleic acid sequence is RNA, which functions as a polypeptide or protein after translation.
- the nucleic acid sequence is DNA, which functions as a protein after forming a protein through the steps of transcription and translation.
- the construct can be packaged into a target cell in the form of virus, lipid nanoparticles or exosomes, or it can enter the target cell by means of electrotransformation, microinjection, chemical transformation and the like.
- the term “delivery” refers to the introduction of biological macromolecules such as nucleic acids and proteins into the cell membrane from outside the cell membrane through certain channels.
- the “delivery” is, for example, electrotransfection, liposome transfection, lipid-nanoparticle delivery, virus delivery, exosomal delivery, and the like.
- modification refers to changing the composition or structure of a nucleic acid or protein by chemical or biological methods, such as genetic engineering methods, so that one or more of the characteristics or functions of the nucleic acid or protein are changed.
- the present application provides a method for targeted editing of IDUA target RNA containing G to A mutations in target cells based on LEAPER technology, which includes: recruiting RNA (arRNA) or encoding adenosine deaminase containing adenosine deaminase for editing target RNA
- the arRNA construct is delivered to the target cell, wherein the arRNA includes a complementary RNA sequence that hybridizes with the target RNA, and wherein the arRNA can recruit adenosine deaminase (ADAR) that acts on RNA to make
- the target adenosine (A) in the target RNA is deaminated.
- the target RNA is a mRNA precursor.
- the target RNA is mature mRNA. In some embodiments, the target RNA is an IDUA target RNA transcribed with a mutation site containing NM_000203.4 (IDUA)-c.1205G-A (p.Trp402Ter).
- the arRNA includes bases C, A, U, or G that pair with target A.
- the preferred sequence of the bases paired with target A is C, A, U, G. That is, when the length of the arRNA is the same, the distance between the target base and the 5'end is the same, the distance between the target base and the 3'end is the same, and the arRNA sequence except the target base is identical, the preferred base is The order is C>A>U>G.
- the arRNA can be expressed as X nt-cY nt, where X indicates that the distance between the target base and the 5'end of the arRNA is X nt, and Y indicates the target base The distance between the base and the 3'end of the arRNA is Y nt, where X and Y can represent any natural numbers.
- the target cell is a eukaryotic cell. In some embodiments, the target cell is a mammalian cell. In some embodiments, the target cells are hepatocytes or fibroblasts. In some embodiments, the target cell is a human or mouse cell.
- the arRNA is about 151-61 nt, 131-66 nt, 121-66 nt, 111-66 nt, 91-66 nt, or 81-66 nt in length.
- the length of the target base in the arRNA from the 3'end is 45-5nt, 40-5nt, 35-10nt, 25nt-15n or 24nt-11nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt.
- the length of the target base from the 3'end refers to the number of all bases from the 3'nearest neighbor base of the target base to the 3'most terminal base; the target base distance is 5'
- the length of the end refers to the number of all bases from the 5'nearest base to the 5'most terminal base of the targeted base.
- the target cell is a human cell
- the target RNA is an IDUA target RNA transcribed with a mutation site of NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter)
- the full length of the arRNA is greater than or equal to 66 nt, such as about 121-66 nt, 111-66 nt, 101-66 nt, 91-66 nt, or 81-66 nt in length, that is, the full length of the arRNA is selected from any natural number in the above-mentioned length range, for example : 67nt, 68nt, 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, 79nt, 80nt, 81nt, 82nt, 83nt, 84nt, 85nt, 86
- the length of the target base in the arRNA from the 3'end is 45-5nt, 40-5nt, 35-10nt, 25nt-15nt or 24nt-11nt, which is the target base distance of the arRNA
- the distance from the 3'end is selected from any natural number in the range of the above-mentioned target base to the 3'end, for example: 12nt, 13nt, 14nt, 16nt, 17nt, 18nt, 19nt, 20nt, 21nt, 22nt, 23nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt, which is the target base distance of the arRNA
- the distance from the 5'end is selected from any natural number in the range of the above-mentioned target base to the 5'end, for example: 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt.
- the arRNA includes a sequence selected from: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 22. SEQ ID NO: 23, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 34.
- the target cell is a mouse cell (eg, W392X mouse cell), and wherein the target RNA is a target RNA transcribed with an IDUA mutation corresponding to the human W402X mutation. In some embodiments, the target cell is a W392X mouse cell.
- the arRNA is about 121-53 nt, 111-61 nt, 101-61 nt, 91-61 nt, 81-61 nt, 111-66 nt, or 105-66 nt in length, that is, the full length of the arRNA is selected from the above Any natural number in the length range, for example: 67nt, 68nt, 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, 79nt, 80nt, 81nt, 82nt, 83nt, 84nt, 85nt, 86nt, 87nt, 88nt, 89nt, 90nt, 91nt, 95nt, 100nt, 110nt, 115nt, 120nt.
- the length of the target base in the arRNA from the 3'end is 55nt-10nt or 50nt-10nt, that is, the distance between the target base of the arRNA and the 3'end is selected from the above-mentioned target base distance Any natural number in the 3'end of the length range, for example: 11nt, 12nt, 13nt, 14nt, 16nt, 17nt, 18nt, 19nt, 20nt, 21nt, 22nt, 23nt, 24nt, 25nt, 26nt, 27nt, 28nt, 29nt, 30nt, 31nt , 32nt, 33nt, 34nt, 35nt, 35nt, 37nt, 38nt, 39nt, 40nt, 41nt, 42nt, 43nt, 44nt, 45nt, 46nt, 47nt, 48nt, 49nt, 50nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt, which is the target base distance of the arRNA
- the distance from the 5'end is selected from any natural number in the range of the above-mentioned target base to the 5'end, for example: 33nt, 36nt, 47nt, 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt, 60nt, 65nt , 75nt.
- the arRNA comprises a sequence selected from: SEQ ID NO: 44 or SEQ ID NO: 52.
- the arRNA is chemically modified.
- the chemical modification is 2-O'-methylation and/or phosphorothioate modification.
- the chemical modification is selected from one or more of the following:
- the first 3 and last 3 nucleotides of the sequence were modified by 2 ⁇ -OMe,
- the first 3 and last 3 internucleotide linkages are all phosphorothioate linkages
- the 3'nearest neighbor of the target base is 2'-OMe modified A
- the 5'nearest neighbor of the targeted base is 2'-OMe modified C
- the target base and its 3’ nearest neighbor base and 5’ nearest neighbor base are respectively connected by phosphorothioate bonds
- the first 5 and last 5 nucleotides are modified by 2 ⁇ -OMe, and
- the first 5 and last 5 nucleotide linkages are phosphorothioate linkages.
- a construct encoding the arRNA is a construct containing the arRNA coding sequence.
- the arRNA is transcribed from the construct encoding the arRNA after the construct encoding the arRNA is delivered into the target cell.
- the construct encoding the arRNA is a linear nucleic acid strand, a viral vector or a plasmid.
- the viral vector is an adeno-associated virus (AAV) or a lentivirus.
- the construct encoding the arRNA when the construct encoding the arRNA is delivered into the target cell, it inserts the sequence encoding the arRNA into the target cell genome through homologous recombination or non-homologous recombination, so as to continue Transcription produces the arRNA.
- the sequence encoding the arRNA when the construct encoding the arRNA is delivered into the target cell, the sequence encoding the arRNA is present in the target cell as part of free nucleic acid, so that the sequence encoding the arRNA The arRNA can be transcribed within a certain period of time.
- the delivery is electrotransfection, liposome transfection, or lipid-nanoparticle (LNP) delivery or infection.
- the delivery when the target cell is a liver cell, the delivery is LNP delivery.
- the delivery when the target cell is a fibroblast, the delivery is liposome transfection.
- the delivery concentration of the arRNA is ⁇ 2.5-5 nM, preferably ⁇ 10-20 nM, such as ⁇ 15 nM. In the present application, the delivery concentration refers to the amount of arRNA contained in one volume unit of arRNA and the delivery system where the target cell is located when the arRNA construct is delivered to the target cell.
- the delivery system includes arRNA or a construct thereof, target cells, and a liquid matrix surrounding the arRNA and the target cells.
- the liquid matrix may be a cell culture medium, PBS, or other solution that can maintain a stable survival state of cells for a certain period of time and is isotonic with the cytoplasm.
- the delivery system further includes an agent that can facilitate delivery.
- This application also provides an arRNA, which can be used for targeted editing of target RNA in target cells based on LEAPER technology, such as transcribed with NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter) mutation site
- the target RNA so that the target A in the target RNA is deaminated is called hypoxanthine I.
- I will be recognized as G, so that the G>A mutation is restored to G, so that the target RNA can be translated into the correct protein after arRNA editing.
- the target RNA is a mRNA precursor.
- the target RNA is mature mRNA.
- the editing efficiency of the bases (target bases) that the arRNA introduces to pair with the target A is C, A, U, G from large to small.
- other bases can be complementary paired with the target RNA.
- one or more bases in the arRNA form a mismatch with the target RNA.
- the target cell is a eukaryotic cell. In some embodiments, the target cell is a mammalian cell. In some embodiments, the target cells are hepatocytes or fibroblasts. In some embodiments, the target cell is a human or mouse cell (e.g., W392X mouse cell).
- the arRNA is about 151-61 nt, 131-66 nt, 121-66 nt, 111-66 nt, 91-66 nt, or 81-66 nt in length.
- the length of the target base in the arRNA from the 3'end is 45-5nt, 40-5nt, 35-10nt, 25nt-15n or 24nt-11nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt.
- the length of the target base from the 3'end refers to the number of all bases from the 3'nearest neighbor base of the target base to the 3'most terminal base; the target base distance is 5'
- the length of the end refers to the number of all bases from the 5'nearest base to the 5'most terminal base of the targeted base.
- the target cell is a human cell
- the target RNA is an IDUA target RNA transcribed with a mutation site of NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter)
- the full length of the arRNA is greater than or equal to 66 nt, such as about 121-66 nt, 111-66 nt, 101-66 nt, 91-66 nt, or 81-66 nt in length, that is, the full length of the arRNA is selected from any natural number in the above-mentioned length range, for example : 67nt, 68nt, 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, 79nt, 80nt, 81nt, 82nt, 83nt, 84nt, 85nt, 86
- the length of the target base in the arRNA from the 3'end is 45-5nt, 40-5nt, 35-10nt, 25nt-15nt or 24nt-11nt, which is the target base distance of the arRNA
- the distance from the 3'end is selected from any natural number in the range of the above-mentioned target base to the 3'end, for example: 12nt, 13nt, 14nt, 16nt, 17nt, 18nt, 19nt, 20nt, 21nt, 22nt, 23nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt, which is the target base distance of the arRNA
- the distance from the 5'end is selected from any natural number in the range of the above-mentioned target base to the 5'end, for example: 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt.
- the arRNA includes a sequence selected from: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 22. SEQ ID NO: 23, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 34.
- the target cell is a mouse cell (such as a W392X mouse cell), and wherein the target RNA is a target RNA transcribed with an IDUA mutation corresponding to the human W402X mutation, then the arRNA is about 121-53nt, 111-61nt, 101-61nt, 91-61nt, 81-61nt, 111-66nt, or 105-66nt, that is, the full length of the arRNA is selected from any natural number in the above-mentioned length range, for example: 67nt, 68nt , 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, 79nt, 80nt, 81nt, 82nt, 83nt, 84nt, 85nt, 86nt, 87nt, 88nt, 89nt, 90n
- the length of the target base in the arRNA from the 3'end is 55nt-10nt or 50nt-10nt, that is, the distance between the target base of the arRNA and the 3'end is selected from the above-mentioned target base distance Any natural number in the 3'end of the length range, for example: 11nt, 12nt, 13nt, 14nt, 16nt, 17nt, 18nt, 19nt, 20nt, 21nt, 22nt, 23nt, 24nt, 25nt, 26nt, 27nt, 28nt, 29nt, 30nt, 31nt , 32nt, 33nt, 34nt, 35nt, 35nt, 37nt, 38nt, 39nt, 40nt, 41nt, 42nt, 43nt, 44nt, 45nt, 46nt, 47nt, 48nt, 49nt, 50nt.
- the length of the target base in the arRNA from the 5'end is 80-30nt, 70-35nt, 60-40nt, 55nt-35nt or 55nt-45nt, which is the target base distance of the arRNA
- the distance from the 5'end is selected from any natural number in the range of the above-mentioned target base to the 5'end, for example: 33nt, 36nt, 47nt, 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt, 60nt, 65nt , 75nt.
- the arRNA comprises a sequence selected from: SEQ ID NO: 44 or SEQ ID NO: 52.
- the arRNA is transcribed and expressed from a construct encoding the arRNA. In some embodiments, the arRNA is transcribed and expressed in vitro from a construct encoding the arRNA, and is obtained by purification. In some embodiments, the arRNA is directly expressed in vivo by the construct encoding the arRNA and exerts an editing function. In some embodiments, the construct is selected from viral vectors, plasmids, and linear nucleic acids. In some embodiments, the virus is AAV or lentivirus.
- the arRNA is chemically synthesized. In some embodiments, the arRNA is chemically modified. In some embodiments, the chemical modification is 2-O'-methylation and/or phosphorothioate modification. In some embodiments, the chemical modification is selected from one or more of the following:
- the first 3 and last 3 nucleotides of the sequence were modified by 2 ⁇ -OMe,
- the first 3 and last 3 internucleotide linkages are all phosphorothioate linkages
- the 3'nearest neighbor of the target base is 2'-OMe modified A
- the 5'nearest neighbor of the targeted base is 2'-OMe modified C
- the target base and its 3’ nearest neighbor base and 5’ nearest neighbor base are respectively connected by phosphorothioate bonds
- the first 5 and last 5 nucleotides are modified by 2 ⁇ -OMe, and
- the first 5 and last 5 nucleotide linkages are phosphorothioate linkages.
- the chemical modification is selected from one or more of the following:
- CM1 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time, all U in the sequence are 2 ⁇ -OMe. ⁇ -OMe modification;
- CM2 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 3'of the base is targeted The nearest neighbor base is 2 ⁇ -OMe modified A;
- CM3 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 5'of the base is targeted The nearest neighbor base is 2 ⁇ -OMe modified C;
- CM4 The first 3 and last 3 nucleotides of the sequence are modified by 2'-OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the target base and its 3' The nearest neighbor base and the 5'nearest neighbor base are respectively connected by phosphorothioate bonds; and
- CM6 The first 5 and last 5 nucleotides of the sequence are modified by 2'-OMe respectively, and the connections between the first 5 and last 5 nucleotides are phosphorothioate linkages.
- the application also provides a construct encoding the aforementioned arRNA.
- the construct is selected from viral vectors, plasmids, and linear nucleic acids.
- the viral vector is an AAV vector or a lentiviral expression vector.
- the application further provides viruses including the constructs, up to nanoparticles, liposomes, exosomes or cells.
- compositions, preparations and biological products containing any of the foregoing arRNA or any of the foregoing constructs which can be used to edit target cells transcribed with NM_000203.4(IDUA)-c.1205G-A( p.Trp402Ter) target RNA at the mutation site to restore the normal function of the IDUA gene.
- the arRNA or construct is encapsulated in liposomes.
- the arRNA or the construct is prepared to form lipid nanoparticles.
- the arRNA or the construct is introduced into the subject by a viral delivery method (for example, adeno-associated virus or lentivirus).
- the arRNA-containing preparation is a therapeutic agent, which can be infused into a patient for the treatment of diseases.
- the infusion is local injection, local infusion or intravenous infusion, local infusion or local injection.
- the agent is in a dosage form suitable for local injection into the liver, such as hepatic arterial perfusion.
- the medicament is in a dosage form suitable for intramuscular injection. In some embodiments, the medicament is in a dosage form suitable for intravenous injection.
- the application also provides a kit for editing target RNA in target cells, which comprises the aforementioned arRNA, the aforementioned construct encoding the arRNA, or the aforementioned preparation.
- the kit can be used for targeted editing of target RNA transcribed with NM_000203.4 (IDUA)-c.1205G-A (p.Trp402Ter) mutation site in target cells.
- the kit comprises the aforementioned arRNA or the aforementioned construct encoding the arRNA, and a dye-assisting reagent, and the arRNA or construct and the dye-assisting reagent are packaged in different Container.
- the dye-assisting reagent is a lipid solution.
- Lipo lipofectmine RNAiMAX catalog number: 13778150
- reagents with the same functional ingredients are packaged in different Container.
- the kit further includes instructions for use to inform the user of the various components contained in the kit and their contents, and/or the method of using the kit.
- the present application further provides a method for treating mucopolysaccharidosis type IH in an individual, which includes correcting the G to A mutation of IDUA gene in individual cells using the method as described above, such as NM_000203.4 (IDUA) -c.1205G-A (p.Trp402Ter) mutation.
- the disease includes Heller's syndrome.
- the frequency of use of arRNA is ⁇ 21 days/time, ⁇ 17 days/time, ⁇ 14 days/time, or ⁇ 10 days/time.
- the individual is a mouse
- the frequency of use of arRNA is ⁇ 8 days/time.
- the therapy uses a construct encoding the arRNA, and the construct can integrate the sequence encoding the arRNA into a target cell, then the frequency of use of the arRNA is single.
- This method does not rely on the expression of foreign proteins, so it will not be difficult to load through viral vectors and deliver in humans due to excessive protein molecular weight; it will not cause off-target effects due to overexpression of foreign proteins; no Causes the body's immune response and damage caused by the expression of foreign proteins; it will not neutralize the foreign editing enzymes or effector proteins due to the pre-existing antibodies in the body, which will cause gene editing to fail.
- RNA editing is reversible and controllable.
- diseases can be treated, and protein and RNA functions can be studied. Because the potential side effects of RNA editing are reversible, it is safer.
- this method can not only chemically synthesize arRNA and complete it by electrotransfection or liposome transfection, but also can be delivered to patients through adeno-associated virus (AAV), lentivirus and other vectors to perform functions , which makes the choice of delivery methods more flexible and more efficient in editing.
- AAV adeno-associated virus
- the editing arRNA was synthesized by Synthego or Suzhou Beixin Biotechnology Co., Ltd., Sanger sequencing was completed by Beijing Ruibo Biotechnology Co., Ltd., and the second-generation sequencing was completed by Nuohe Zhiyuan Bioinformatics Co., Ltd. or the sequencing platform of Rice Research Institute of Chinese Academy of Sciences. .
- GM06214 cells fibroblasts derived from Hurler syndrome patients
- fibroblast culture medium ScienCell, FM medium, catalog number: 23011
- Fibroblast growth supplement ScienCell, GFS, catalog number: 2301
- NCBI-Primer blast URL: https://www.ncbi.nlm.nih.gov/tools/primer-blast/
- SEQ ID NO 1 CGCTTCCAGGTCAACAACAC (forward primer hIDUA-F1)
- SEQ ID NO 2 CTCGCGTAGATCAGCACCG (reverse primer hIDUA-R1).
- the PCR reaction was performed, and the PCR product was subjected to Sanger sequencing. It is determined that the mutant type of the cell is the pathogenic type where G at position 15704 in the IDUA genome changes to A, as shown in Figure 1.
- Example 2 Screening of electrotransfection conditions for GM06214 cells
- Cells of each condition are divided into 2 wells (6-well plates) and seeded in the culture plate. Place the cells Cultivate in a 37°C, 5% CO2 incubator. 24 hours after electrotransfection, digest one well of cells in each of the 2-well cells under electrotransfection conditions, and use flow cytometry to measure the proportion of GFP-positive cells. 48 hours after electrotransfection After hours, digest the cells in the other well of the two-well cells in each electrotransfection condition, and measure the proportion of GFP-positive cells by flow cytometry. The best electrotransfection conditions for the cells are the electrotransfection conditions of the CA-137 group ,as shown in picture 2.
- Example 3 Study on IDUA enzyme activity and editing efficiency of GM06214 cells electrotransfected with arRNA
- SEQ ID NO 3 GACGCCCACCGUGUGGUUGCUGUCCAGGACGGUCCCGGCCUGCGACACUUCGGCCCAGAGCUGCUCCUCAUCCAGCAGCGCCAGCAGCCCCAUGGCCGUGAGCACCGGCUU (Pre-55nt-c-55nt);
- SEQ ID NO 4 GACGCCCACCGUGUGGUUGCUGUCCAGGACGGUCCCGGCCUGCGACACUUCGGCCCAGAGCUGCUCCUCAUCUGCGGGGCGGGGGGGGGCCGUCGCCGCGUGGGGUCGUUG (m-55nt-c-55nt);
- SEQ ID NO 5 UACCGCUACAGCCACGCUGAUUUCAGCUAUACCUGCCCGGUAUAAAGGGACGUUCACACCGCGAUGUUCUCUGCUGGGGAAUUGCGCGAUAUUCAGGAUUA
- Buffer RLT Plus 0.35ml of Buffer RLT Plus to 5 ⁇ 10 5 cells by pipetting and mix well (if cryopreserved cells directly extract RNA, it is recommended to wash once with PBS).
- RNA concentration of the extracted RNA was measured with Nanodrop (Thermo, article number: Nanodrop2000), and 1ug of RNA was used for reverse transcription (Thermo, article number of reverse transcriptase: 28025013).
- the GM06214 cells were digested and centrifuged, and resuspended in 28 ul of 1 ⁇ PBS containing 0.1% Triton X-100 on ice for 30 minutes. Then add 25ul of cell lysate to 25ul containing 190 ⁇ m 4-methylumbelliferyl- ⁇ -L-iduronidase (Cayman, 2A-19543-500) , Dissolved in 0.4M sodium formate buffer, containing 0.2% Triton X-100, PH3.5). Incubate at 37°C for 90 minutes in the dark.
- GM01323 cells are fibroblasts derived from patients with Scheie syndrome.
- Scheie syndrome is a milder form of mucopolysaccharidosis, and the symptoms are much milder than Hurler syndrome.
- Patients with Scheie syndrome tend to have a better prognosis, with a normal life span and can live to adulthood.
- the IDUA enzyme activity in fibroblasts of patients with Scheie syndrome is 0.3% of that in healthy human wild-type fibroblasts.
- the results show that when arRNA targets mRNA precursor (pre-mRNA), it can show higher enzyme activity and editing efficiency, while arRNA targeting mature mRNA (mature-mRNA) shows significantly lower Enzyme activity and editing efficiency. Therefore, the arRNAs involved in the following examples are all targeting mRNA precursors (pre-mRNA).
- Example 4 IDUA target site editing efficiency after electrotransfection of arRNA on IDUA-reporter cell line Detection
- a segment carrying the IDUA mutation site and the upstream and downstream sequences of about 100 bp were inserted to construct the plasmid.
- the above constructed plasmid was packaged into a virus, and 293T cells were infected. After it was integrated into the genome, IDUA-reporter monoclonal cells were screened out. This monoclonal cell only expresses mCherry protein because of the influence of the TAG stop codon at the IDUA mutation site in the inserted sequence, and when the cell is edited by arRNA, TAG->TGG occurs, and the GFP protein behind it can be expressed normally.
- GFP Protein expression can be regarded as the editing efficiency of arRNA editing cells.
- Example 5 After arRNA of different lengths are electrotransfected into GM06214 cells, the detection of different time points Intracellular IDUA enzyme activity and intracellular RNA editing efficiency
- Example 2 Using the electrotransfection conditions of Example 2 to electrotransfect arRNA of different lengths on GM06214 cells (see Table 4), according to the method in Example 3, the second, fourth, sixth, eighth, and tenth sections were respectively electrotransfected after electrotransfection. , The enzyme activity in the cell was tested on the 12th and 14th day, and the editing efficiency of the intracellular RNA was tested on the 2nd and 4th day. From the results, as shown in Figure 5, 91nt:45-c-45 has the highest enzyme activity, and the IDUA enzyme activity is still maintained at a high level on the 6th day after electrotransfection. In terms of editing efficiency, 91nt and 111nt show roughly the same editing efficiency.
- Example 6 Editing efficiency of editing site A corresponding to different positions of arRNA
- both ends of the mutation site are simultaneously truncated and the 5'end or the 3'end are respectively truncated to study the editing efficiency of the target base corresponding to different positions of the arRNA.
- lipofectmine RNAiMAX was used to introduce arRNA into cells.
- RNA editing efficiency is better than other sequences, as shown in Figure 6.
- Example 7 The effect of the length from the 3'end of the target base on editing efficiency
- Example 6 higher IDUA enzyme activity and editing efficiency were detected on the 81nt:55-c-25 and 71nt:55-c-15 sequences.
- the 3'end starts from 25nt (81nt:55-c-25) to 10nt (66nt:55nt-c-10nt) from the target base. Truncate one by one, as shown in Table 6.
- the optimal length of the target base from the 3'end of the IDUA enzyme activity assay was selected to be 24 nt to 11 nt, as shown in Figure 7A.
- the arRNA targeting the mouse IDUA mutation site (the mutation site corresponding to the human IDUA-W402X mutation) for the optimal length of the target base distance from the 3'end, and arRNA's 3 ⁇ The length of the target base starts from 55nt and is truncated every 5 bases, as shown in Table 7.
- IDUA enzyme activity it was selected that the length of the target base from the 3'end in the mouse was 55 nt-10 nt, and the optimal length was 55 nt-10 nt, as shown in Figure 7B.
- 111nt: 55nt-c-50nt (SEQ ID NO: 44) and 66nt: 55nt-c-10nt (SEQ ID NO: 52) show superior editing efficiency.
- RNA modifications can increase the stability of RNA and reduce the possibility of off-target.
- the more common chemical modifications to RNA are 2 ⁇ -OMe and thiosulfide.
- CM1 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time, all U in the sequence are 2 ⁇ -OMe. ⁇ -OMe modification.
- CM2 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 3'of the base is targeted The nearest neighbor base is 2'-OMe modified A.
- CM3 The first 3 and last 3 nucleotides of the sequence are modified by 2 ⁇ -OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the 5'of the base is targeted The nearest neighbor base is 2'-OMe modified C.
- CM4 The first 3 and last 3 nucleotides of the sequence are modified by 2'-OMe respectively, the connections between the first 3 and the last 3 nucleotides are all phosphorothioate linkages; at the same time the target base and its 3' The nearest neighbor base and the 5'nearest neighbor base are respectively connected by phosphorothioate bonds.
- CM5 All nucleotides are modified by 2 ⁇ -OMe except for the target base, the 5 bases adjacent to the 5'end and the 5 bases adjacent to the 3'end, all nucleotides are modified by 2 ⁇ -OMe; at the same time the first 3 of the sequence The connections between the first and last 3 nucleotides are all phosphorothioate linkages.
- CM6 The first 5 and last 5 nucleotides of the sequence are modified by 2'-OMe respectively, and the connections between the first 5 and last 5 nucleotides are phosphorothioate linkages.
- ro represents that the nucleotide is not modified and the ester bond between the nucleotide is not modified
- r* represents that the nucleotide is not modified and the nucleotide is connected by phosphorothioate bond
- mo It represents that the nucleotides are modified by 2'-OMe and the ester bonds between the nucleotides are not modified
- m* represents that the nucleotides are modified by 2'-OMe and the nucleotides are connected by phosphorothioate bonds.
- This example relates to 3 preferred arRNAs targeting the mutation site of human IDUA and 1 preferred arRNA targeting the mutation site of mouse IDUA.
- the chemical modification method in CM1 mode is used in GM06214 cells and MSPI MEF (MSPI mouse embryos).
- Fibroblasts (MSPI mouse embryo fibroblast, MEF), isolated from IDUA homozygous mutant fetal mice (idua W392X mouse, B6.129S-Idua tm1.1Kmke /J) (Wang D, Shukla C, Liu X, et al .Characterization of an MPS IH knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation[published correction appears in Mol Genet Metab.2010Apr;99(4):439].Mol Genet Metab.2010;99( 1): 62-71. doi: 10.1016/j.ymgme.2009.08.002)) Concentration gradient experiment on cells.
- Example 7 From the experimental results of Example 7, we selected 3 arRNAs that target human IDUA, the lengths are: 55nt-c-16nt, 55nt-c-14nt, 55nt-c-11nt, 1 target mouse IDUA ArRNA: 55nt-c-10nt. In addition, we also selected the random arRNA sequence RM-67CM1 as a control. From Example 9, we selected the chemical modification method of CM1 (all u: 2'-OMe) to synthesize the above-mentioned IDUA-targeted arRNA, as shown in Table 9. We performed arRNA concentration gradient transfection on human GM06214 cells compared with MSPI mouse MEF.
- the concentration of arRNA is: 160nM, 80nM, 40nM, 20nM, 10nM, 5nM, 2.5nM, 1.25nM, 0.625nM in 9 concentrations.
- the cells were spread in a 6-well plate and transfected 24hrs after plating. Cells were digested 48hrs after transfection. Half of the cells were tested for IDUA enzyme activity and half of the cells were extracted for RNA editing efficiency testing.
- ro represents no modification on the nucleotides and no modification of the ester bond between the nucleotides
- r* represents no modification on the nucleotides and the connection between the nucleotides with phosphorothioate bond
- mo represents the nucleus The nucleotides are connected with 2 ⁇ -OMe modified nucleotides without modification
- m* represents that the nucleotides are connected with 2 ⁇ -OMe modified nucleotides with phosphorothioate bonds.
- Example 11 IDUA can sustain protease activity after arRNA editing
- Fibroblast cells have significantly improved IDUA enzyme activity, and it can last for more than 3 weeks.
- Example 10 we performed a comparison of the arRNA targeting IDUA in humans and mice at different concentrations 48hrs after transfection.
- FIG 11A after arRNA was transfected into GM06214 cells, we continuously detected IDUA enzyme activity for 14 days. The peak of enzyme activity after transfection was from day 4 to day 9, and the enzyme activity on day 14 was still higher than that on day 2. , And then we tested at a longer time point for 2 days, namely the 17th day and the 21st day after transfection. From Figure 10A, it can be seen that the enzyme activity on day 21 is still higher than that on day 1 after transfection.
- the enzyme activity is about 6 to 10 times that of GM01323. (Editing efficiency needs to be supplemented, Figure 11B).
- Figure 11C the enzymatic activity at 24hrs after arRNA transfection is about twice that of GM1323 cells until day 8. From Figure 11D It can be seen from the editing efficiency test of IDUA that IDUA's editing efficiency peaked at 24hrs, and then continued to decline.
- This experiment involves using LEAPER technology to edit wild-type PPIB gene loci on primary cultured human and mouse liver cells, and deliver arRNA in different ways to screen out the optimal delivery method.
- PPIB refers to the wild site in the UTR region of human NM_000942 (PPIB Genomic chr15(-): 64163082) or the wild site in the UTR region of mouse NM_011149 (PPIB Genomic chr9(+): 66066490). It can be mature mRNA or mRNA precursor. There is a TAG in the UTR segment of PPIB. In this embodiment, A in the TAG is used as a target for editing to test the editing efficiency of the arRNA in this application in liver cells.
- Human liver cells were resuscitated 24hrs for arRNA delivery, and the delivery concentrations of LNP and Lipo were both 20nM.
- Mouse liver cells were isolated and cultured for 24hrs and then delivered arRNA. The delivery concentrations of LNP and Lipo were both 20nM.
- Human and mouse liver cells collected RNA at 24hrs and 48hrs after arRNA delivery, and the editing efficiency was tested by next-generation sequencing. It can be seen from Fig. 12A that in human liver cells, the editing efficiency of 48hrs after the two methods of arRNA delivery is higher than 24hrs, and the editing efficiency of arRNA delivered by LNP is better than that of Lipo delivery at 24hrs. Both 48hrs. The editing efficiency of the delivery method is similar.
- This experiment involves studying the editing efficiency of IDUA using LNP to deliver IDUA arRNA on primary cultured human and mouse liver cells.
- mice homozygous for this mutation are viable and fertile, their average life span is 69 weeks. Homozygotes show a progressive increase in the excretion of glycosaminoglycans (GAGs) in the urine and a progressive accumulation of GAGs in the tissues. Steady state Idua mRNA levels are reduced by 30-50%.
- GAGs glycosaminoglycans
- mice liver cells were taken for IDUA editing efficiency test, as shown in Figure 14.
- the editing efficiency of about 2% can be detected in the 10 mg/kg group 24 hours after administration.
- the result of this example proves that the arRNA directed to the IDUA of the MSPI model mouse can achieve precise editing of the mutated IDUA gene in liver cells in vivo, correct the IDUA mutation, and achieve the purpose of treating MPSI.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Detergent Compositions (AREA)
Abstract
Description
体积(ul) | |
总RNA(1ug) | X |
Oligo dT | 1 |
10nM dNTP | 1 |
RNase-Free Water | 10-X |
总体积 | 12 |
Claims (23)
- 一种基于LEAPER技术靶向编辑靶标细胞中靶标RNA的方法,其中所述靶标RNA为IDUA基因转录本中含有G到A突变的RNA,该方法包括:将包含用于编辑靶标RNA的腺苷脱氨酶募集RNA(arRNA)或编码所述arRNA的构建体递送至所述靶标细胞,其中所述arRNA包含与所述靶标RNA杂交的互补RNA序列,并且其中所述arRNA能够募集作用于RNA的腺苷脱氨酶(ADAR)以使靶标RNA中的靶标腺苷(A)脱氨基。
- 如权利要求1中所述的方法,其中所述arRNA包含与靶标A配对的碱基C、A、U或G。
- 如权利要求1-2中任一项所述的方法,其中所述arRNA长约151-61nt、131-66nt、121-66nt、111-66nt、91-66nt或81-66nt。
- 如权利要求3中所述的方法,其中所述arRNA中靶向碱基距离3’端的长度为45-5nt,40-5nt,35-10nt,25nt-15n或24nt-11nt。
- 如权利要求3或4中所述的方法,其中所述arRNA中靶向碱基距离5’端的长度为80-30nt,70-35nt,60-40nt,55nt-35nt或55nt-45nt。
- 如权利要求1-5中所述的方法,其中所述靶标细胞是人的细胞。
- 权利要求1-6中任一项的方法,其中所述靶标RNA为包含NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter)突变位点的RNA。
- 权利要求1-7中任一项的方法,其中所述arRNA包含以下的序列:SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:9、SEQ ID NO:13、SEQ ID NO:17、SEQ ID NO:22、SEQ ID NO:23、SEQ ID NO:30、SEQ ID NO:31或SEQ ID NO:34。
- 如权利要求1-5中任一项所述的方法,其中所述arRNA包含选自以下的序列:SEQ ID NO:44或SEQ ID NO:52。
- 如权利要求1-9中任一项所述的方法,其中所述arRNA是经化学修饰的。
- 如权利要求10中所述的方法,其中所述化学修饰包含2-O’-甲基化(2`-OMe)或硫代磷酸酯修饰。
- 如权利要求11中所述的方法,其中所述化学修饰选自如下的一项或多项:序列前3个和后3个核苷酸分别被2`-OMe修饰,前3个和后3个核苷酸间连接均为硫代磷酸酯键连接,序列中全部U均被2`-OMe修饰,靶向碱基的3’最近邻碱基为2`-OMe修饰的A,靶向碱基的5’最近邻碱基为2`-OMe修饰的C,靶向碱基与其3’最近邻碱基和5’最近邻碱基分别以硫代磷酸酯键连接,前5个和后5个核苷酸分别被2`-OMe修饰,和前5个和后5个核苷酸间连接为硫代磷酸酯键连接。
- 如权利要求1-9中任一项所述的方法,其中所述编码所述arRNA的构建体为线性核酸链、病毒载体或质粒。
- 如权利要求13中所述的方法,其中所述病毒载体为腺相关病毒(AAV)载体或慢病毒表达载体。
- 如权利要求1-14中任一项所述的方法,其中所述递送方式为电转染、脂质体转染、脂质-纳米颗粒(lipid nanoparticle,LNP)递送或感染。
- 如权利要求15中所述的方法,通过LNP将包含用于编辑靶标RNA的腺苷脱氨酶募集RNA(arRNA)或编码所述arRNA的构建体递送至所述靶标细胞。
- 如权利要求1-16中任一项所述的方法,其中所述arRNA的递送浓度≥2.5,≥5nM,≥10nM,≥15nM,或≥20nM。
- 一种用于通过LEAPER技术靶向编辑靶标细胞中靶标RNA的arRNA或其编码序列,所述arRNA包含如下任一序列或由如下任一序列组成:SEQ ID NO:14、SEQ ID NO:15、SEQ ID NO:9、SEQ ID NO:13、SEQ ID NO:17、SEQ ID NO:22、SEQ ID NO:23、SEQ ID NO:30、SEQ ID NO:31、SEQ ID NO:34、SEQ ID NO:44或SEQ ID NO:52。
- 包含权利要求18所述arRNA或其编码序列的质粒、病毒载体、脂质体或脂质纳米颗粒。
- 包含权利要求18所述arRNA或其编码序列、或权利要求19所述质粒、病毒载体、脂质体或脂质纳米颗粒的组合物或生物制品。
- 一种治疗个体中MPS IH的方法,包括用权利要求1-17中任一项所述的方法校正所述个体的靶标细胞中与MPS IH疾病相关的G到A的突变。
- 权利要求20的方法,其中所述突变为NM_000203.4(IDUA)-c.1205G-A(p.Trp402Ter)突变。
- 如权利要求20或21所述的方法,其中所述arRNA的使用频次为≥21天/次、≥17天/次、≥14天/次或≥10天/次。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL294201A IL294201A (en) | 2019-12-30 | 2020-12-30 | A method based on leaper technology to treat mps ih and a preparation |
CN202080086708.7A CN114846139A (zh) | 2019-12-30 | 2020-12-30 | 一种基于leaper技术治疗mps ih的方法和组合物 |
CA3163272A CA3163272A1 (en) | 2019-12-30 | 2020-12-30 | Leaper technology based method for treating mps ih and composition |
US17/790,487 US20230060518A1 (en) | 2019-12-30 | 2020-12-30 | Leaper technology based method for treating mps ih and composition |
PE2022001378A PE20230037A1 (es) | 2019-12-30 | 2020-12-30 | Metodo basado en tecnologia leaper para el tratamiento de mucopolisacaridosis ih y composicion |
CR20220365A CR20220365A (es) | 2019-12-30 | 2020-12-30 | Método basado en tecnología leaper para el tratamiento de mucopolisacaridosis ih y composición |
JP2022540985A JP2023509179A (ja) | 2019-12-30 | 2020-12-30 | Leaper技術に基づくmps ihの治療方法及び組成物 |
EP20908810.3A EP4086345A4 (en) | 2019-12-30 | 2020-12-30 | METHOD BASED ON LEAPER TECHNOLOGY FOR PROCESSING MPS IH AND COMPOSITION |
KR1020227025378A KR20220119129A (ko) | 2019-12-30 | 2020-12-30 | Leaper 기술에 기반한 mps ih 치료 방법 및 조성물 |
MX2022008190A MX2022008190A (es) | 2019-12-30 | 2020-12-30 | Metodo basado en tecnologia leaper para el tratamiento de mucopolisacaridosis ih y composicion. |
AU2020418228A AU2020418228A1 (en) | 2019-12-30 | 2020-12-30 | Leaper technology based method for treating MPS IH and composition |
CONC2022/0010432A CO2022010432A2 (es) | 2019-12-30 | 2022-07-26 | Método basado en tecnología leaper para el tratamiento de mucopolisacaridosis ih y composición |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019129952 | 2019-12-30 | ||
CNPCT/CN2019/129952 | 2019-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136408A1 true WO2021136408A1 (zh) | 2021-07-08 |
Family
ID=76687311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/141506 WO2021136408A1 (zh) | 2019-12-30 | 2020-12-30 | 一种基于leaper技术治疗mps ih的方法和组合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230060518A1 (zh) |
EP (1) | EP4086345A4 (zh) |
JP (1) | JP2023509179A (zh) |
KR (1) | KR20220119129A (zh) |
CN (1) | CN114846139A (zh) |
AU (1) | AU2020418228A1 (zh) |
CA (1) | CA3163272A1 (zh) |
CL (1) | CL2022001776A1 (zh) |
CO (1) | CO2022010432A2 (zh) |
CR (1) | CR20220365A (zh) |
EC (1) | ECSP22059741A (zh) |
IL (1) | IL294201A (zh) |
MX (1) | MX2022008190A (zh) |
PE (1) | PE20230037A1 (zh) |
TW (1) | TW202128193A (zh) |
WO (1) | WO2021136408A1 (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11661596B2 (en) | 2019-07-12 | 2023-05-30 | Peking University | Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs |
US11702658B2 (en) | 2019-04-15 | 2023-07-18 | Edigene Therapeutics (Beijing) Inc. | Methods and compositions for editing RNAs |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024084048A1 (en) | 2022-10-21 | 2024-04-25 | Proqr Therapeutics Ii B.V. | Heteroduplex rna editing oligonucleotide complexes |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
WO2024115635A1 (en) | 2022-12-01 | 2024-06-06 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
US12018257B2 (en) | 2016-06-22 | 2024-06-25 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
WO2024153801A1 (en) | 2023-01-20 | 2024-07-25 | Proqr Therapeutics Ii B.V. | Delivery of oligonucleotides |
WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
WO2024200278A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Chemically modified antisense oligonucleotides for use in rna editing |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230703A1 (es) * | 2020-04-15 | 2023-04-24 | Edigene Therapeutics Beijing Inc | Metodo y farmaco para tratar el sindrome de hurler |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016097212A1 (en) * | 2014-12-17 | 2016-06-23 | Proqr Therapeutics Ii B.V. | Targeted rna editing |
WO2018041973A1 (en) * | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
CN109477103A (zh) * | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
WO2020074001A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and Compositions for Editing RNAs |
WO2020168051A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
WO2020211780A1 (en) * | 2019-04-15 | 2020-10-22 | Edigene Inc. | Methods and compositions for editing rnas |
-
2020
- 2020-12-30 CN CN202080086708.7A patent/CN114846139A/zh active Pending
- 2020-12-30 AU AU2020418228A patent/AU2020418228A1/en active Pending
- 2020-12-30 CR CR20220365A patent/CR20220365A/es unknown
- 2020-12-30 MX MX2022008190A patent/MX2022008190A/es unknown
- 2020-12-30 CA CA3163272A patent/CA3163272A1/en active Pending
- 2020-12-30 PE PE2022001378A patent/PE20230037A1/es unknown
- 2020-12-30 IL IL294201A patent/IL294201A/en unknown
- 2020-12-30 US US17/790,487 patent/US20230060518A1/en active Pending
- 2020-12-30 EP EP20908810.3A patent/EP4086345A4/en active Pending
- 2020-12-30 WO PCT/CN2020/141506 patent/WO2021136408A1/zh unknown
- 2020-12-30 JP JP2022540985A patent/JP2023509179A/ja active Pending
- 2020-12-30 KR KR1020227025378A patent/KR20220119129A/ko not_active Application Discontinuation
- 2020-12-30 TW TW109146923A patent/TW202128193A/zh unknown
-
2022
- 2022-06-29 CL CL2022001776A patent/CL2022001776A1/es unknown
- 2022-07-26 CO CONC2022/0010432A patent/CO2022010432A2/es unknown
- 2022-07-29 EC ECSENADI202259741A patent/ECSP22059741A/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016097212A1 (en) * | 2014-12-17 | 2016-06-23 | Proqr Therapeutics Ii B.V. | Targeted rna editing |
CN109477103A (zh) * | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
WO2018041973A1 (en) * | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
WO2020074001A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and Compositions for Editing RNAs |
WO2020168051A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
WO2020211780A1 (en) * | 2019-04-15 | 2020-10-22 | Edigene Inc. | Methods and compositions for editing rnas |
Non-Patent Citations (13)
Title |
---|
AQUINO-JARQUIN GUILLERMO: "Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 19, 1 March 2020 (2020-03-01), US, pages 1065 - 1072, XP055809492, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2019.12.042 * |
KAUFFMAN K JDORKIN J RYANG J H ET AL.: "Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs[J", NANO LETTERS, vol. 15, no. 11, 2015, pages 7300 - 7306, XP055679418, DOI: 10.1021/acs.nanolett.5b02497 |
MIKI TOSHIO, VAZQUEZ LUDIVINA, YANUARIA LISA, LOPEZ OMAR, GARCIA IRVING M., OHASHI KAZUO, RODRIGUEZ NATALIE S.: "Induced Pluripotent Stem Cell Derivation and Ex Vivo Gene Correction Using a Mucopolysaccharidosis Type 1 Disease Mouse Model", STEM CELLS INTERNATIONAL, HINDAWI PUBLISHING CORPORATION, US, vol. 2019, 1 April 2019 (2019-04-01), US, pages 1 - 10, XP055825935, ISSN: 1687-966X, DOI: 10.1155/2019/6978303 * |
MOL GENET METAB, vol. 99, no. 1, 2010, pages 62 - 71 |
QU LIANG, YI ZONGYI, ZHU SHIYOU, WANG CHUNHUI, CAO ZHONGZHENG, ZHOU ZHUO, YUAN PENGFEI, YU YING, TIAN FENG, LIU ZHIHENG, BAO YING,: "Leveraging Endogenous ADAR for Programmable Editing on RNA", BIORXIV, 19 April 2019 (2019-04-19), XP055825931, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/605972v1.full.pdf> DOI: 10.1101/605972 * |
QU LIANG; YI ZONGYI; ZHU SHIYOU; WANG CHUNHUI; CAO ZHONGZHENG; ZHOU ZHUO; YUAN PENGFEI; YU YING; TIAN FENG; LIU ZHIHENG; BAO YING;: "Author Correction: Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs", NATURE BIOTECHNOLOGY, GALE GROUP INC., NEW YORK, vol. 37, no. 11, 25 September 2019 (2019-09-25), New York, pages 1380 - 1380, XP036920810, ISSN: 1087-0156, DOI: 10.1038/s41587-019-0292-y * |
REIS JKANAGARAJ SFONSECA A ET AL.: "In vitro studies of multiwalled carbon nanotube/ultrahigh molecular weight polyethylene nanocomposites with osteoblast-like MG63 cells[J", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 43, no. 5, 2010, pages 476 - 482 |
SCHUH ROSELENA SILVESTRI; DE CARVALHO TALITA GIACOMET; GIUGLIANI ROBERTO; MATTE URSULA; BALDO GUILHERME; TEIXEIRA HELDER FERREIRA: "Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 122, 6 November 2017 (2017-11-06), NL, pages 158 - 166, XP085322671, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2017.10.017 * |
See also references of EP4086345A4 |
TOLAR, J: "Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler Syndrome", BONE MARROW TRANSPLANTATION, vol. 41, 2008, pages 531 - 5, XP037759180, DOI: 10.1038/sj.bmt.1705934 |
WANG DSHUKLA CLIU X ET AL.: "Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation", MOL GENET METAB, vol. 99, no. 4, April 2010 (2010-04-01), pages 439, XP026954113 |
WITZIGMANN DKULKARNI J ALEUNG J ET AL.: "Lipid nanoparticle technology for therapeutic gene regulation in the liver[J", ADVANCED DRUG DELIVERY REVIEWS, 2020 |
XIANG CDU YMENG G ET AL.: "Long-term functional maintenance of primary human hepatocytes in vitro[J", SCIENCE, vol. 364, no. 6438, 2019, pages 399 - 402 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12018257B2 (en) | 2016-06-22 | 2024-06-25 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
US11702658B2 (en) | 2019-04-15 | 2023-07-18 | Edigene Therapeutics (Beijing) Inc. | Methods and compositions for editing RNAs |
US11661596B2 (en) | 2019-07-12 | 2023-05-30 | Peking University | Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs |
US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024084048A1 (en) | 2022-10-21 | 2024-04-25 | Proqr Therapeutics Ii B.V. | Heteroduplex rna editing oligonucleotide complexes |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
WO2024115635A1 (en) | 2022-12-01 | 2024-06-06 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
WO2024153801A1 (en) | 2023-01-20 | 2024-07-25 | Proqr Therapeutics Ii B.V. | Delivery of oligonucleotides |
WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
WO2024200278A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Chemically modified antisense oligonucleotides for use in rna editing |
WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Also Published As
Publication number | Publication date |
---|---|
EP4086345A4 (en) | 2024-03-20 |
TW202128193A (zh) | 2021-08-01 |
CR20220365A (es) | 2022-12-06 |
CO2022010432A2 (es) | 2022-08-09 |
US20230060518A1 (en) | 2023-03-02 |
ECSP22059741A (es) | 2022-11-30 |
AU2020418228A1 (en) | 2022-08-18 |
CN114846139A (zh) | 2022-08-02 |
CA3163272A1 (en) | 2021-07-08 |
EP4086345A1 (en) | 2022-11-09 |
JP2023509179A (ja) | 2023-03-07 |
KR20220119129A (ko) | 2022-08-26 |
PE20230037A1 (es) | 2023-01-10 |
MX2022008190A (es) | 2022-08-02 |
IL294201A (en) | 2022-08-01 |
CL2022001776A1 (es) | 2023-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021136408A1 (zh) | 一种基于leaper技术治疗mps ih的方法和组合物 | |
WO2021209010A1 (zh) | 一种治疗赫勒氏综合征的方法和药物 | |
US11332726B2 (en) | Permanent gene correction by means of nucleotide-modified messenger RNA | |
WO2021136404A1 (zh) | 一种治疗Usher综合征的方法和其组合物 | |
CN113348245A (zh) | 新型crispr酶和系统 | |
EP1957648B1 (en) | Modulation of gene expression by oligomers targeted to chromosomal dna | |
CN107090456B (zh) | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 | |
KR101835018B1 (ko) | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 | |
JP2021511803A (ja) | ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法 | |
JP2017212982A (ja) | イソクエン酸デヒドロゲナーゼ(idh1)遺伝子発現のrna干渉媒介抑制 | |
CN113528582B (zh) | 基于leaper技术靶向编辑rna的方法和药物 | |
KR20230152014A (ko) | 에어로졸 형성을 위한 제형 및 핵산 전달을 위한 에어로졸 | |
TW202136513A (zh) | 靶向編輯rna的新方法 | |
Weng et al. | Improvement of muscular atrophy by AAV–SaCas9-mediated myostatin gene editing in aged mice | |
CN113122580A (zh) | 一种基于leaper技术治疗mps ih的方法和组合物 | |
WO2023143538A1 (zh) | 基于leaper技术治疗mpsi的方法和组合物 | |
US20220251566A1 (en) | Cells engineered for oligonucleotide delivery, and methods for making and using thereof | |
WO2024169770A1 (zh) | 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途 | |
JP2024531966A (ja) | 操作されたadar動員rna及びその使用方法 | |
CN116515814A (zh) | 基于leaper技术治疗mpsi的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20908810 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3163272 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022540985 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227025378 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020418228 Country of ref document: AU Date of ref document: 20201230 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020908810 Country of ref document: EP Effective date: 20220801 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022012926 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112022012926 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220628 |